GYRE THERAPEUTICS, INC. quarterly report, Q3 FY2012

Business context and reporting period

This is Targacept, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2012, filed November 8, 2012. The filing identifies Targacept—not GYRE Therapeutics, Inc.—as the registrant; confirm that this is the intended filing. Targacept was a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor therapeutics, with collaboration and licensing revenue and no product sales described.

Financial results and liquidity

Amounts below are in millions of dollars except per-share data. No gross margin is reported.

• Nine-month operating cash use was $52.638 million, versus $63.189 million in 2011. Investing activities provided $23.988 million, mainly reflecting net sales of marketable securities; financing used $0.431 million. Cash and cash equivalents fell $29.081 million to $78.202 million.
• Cash, cash equivalents and marketable securities totaled $195.608 million at September 30, 2012, down from $249.270 million at December 31, 2011. Current assets were $148.097 million and current liabilities $9.810 million.
• Total debt was approximately $2.195 million, including $0.844 million current and $1.351 million long-term. Stockholders’ equity was $190.570 million; accumulated deficit was $218.058 million.

Material changes versus prior comparable periods

• Q3 revenue fell $18.187 million year over year, largely because the AstraZeneca TC-5214 upfront payment had been fully recognized by Q2 2012; Q3 2011 included $18.3 million of that revenue.
• Nine-month revenue declined $21.422 million. The 2011 period included recognition of deferred GlaxoSmithKline revenue following termination and TC-5619-related revenue that was no longer recognized in 2012.
• Nine-month 2012 net income included $54.473 million of TC-5214 upfront-payment revenue. The resulting reported profit should be considered alongside the period’s $52.638 million operating cash outflow.
• R&D expense declined substantially as the TC-5214 major-depression program wound down, preclinical spending fell, TC-6987 studies ended, and the company reduced its workforce. Nine-month G&A rose partly because of executive severance and stock-option modification charges.

Outlook, commentary and risks

• Management expected existing capital resources to fund operations through at least the end of 2015, excluding potential AstraZeneca milestones; it cautioned that plans could change and additional capital might be needed sooner. No assurance was given that milestone payments would be achieved.
• Management expected Q4 2012 revenue to be comparable to Q3 and substantially below Q4 2011. It expected full-year R&D expense to decline from 2011, while continuing spending on TC-5619, AZD3480 and preparation for a TC-5214 overactive-bladder study.
• TC-5214’s AstraZeneca collaboration terminated effective in May 2012 after the parties decided not to pursue a major-depression regulatory filing and discontinued the switch-monotherapy trial. Targacept planned a Phase 2b study of TC-5214 in overactive bladder.
• TC-5619 remained in Phase 2b studies for schizophrenia; its ADHD Phase 2 trial missed its primary endpoint, and Targacept said it would not pursue further ADHD development. AZD3480 was in a Phase 2b Alzheimer’s trial. AZD1446 was not in an active clinical trial, with next steps under discussion with AstraZeneca.
• A second workforce reduction and laboratory closure were announced October 8, 2012. The company expected approximately $1.480 million in Q4 severance and other charges and a further 27-employee reduction, leaving approximately 43 employees.
• Key risks include clinical-trial and regulatory uncertainty, dependence on AstraZeneca’s development decisions and collaboration, ability to raise capital or secure new partnerships, and effects of workforce reductions and executive departures. The company reported effective disclosure controls and no material quarterly change in internal control over financial reporting.

Important facts for investors to verify

1. Confirm the registrant identity: this filing is for Targacept, Inc., not GYRE Therapeutics, Inc.
2. Assess the non-recurring nature of collaboration revenue and the extent to which reported nine-month profit reflects deferred-revenue recognition rather than cash generation.
3. Verify subsequent execution and costs of the October 2012 workforce reduction and laboratory closure.
4. Check clinical and partner updates for TC-5619, AZD3480 and AZD1446, including AstraZeneca’s decisions and any milestone prospects.
5. Reassess cash burn and runway against management’s end-of-2015 estimate, which excludes milestone receipts and depends on operating plans and development costs.